Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure (AJMC)
Diabetes News Service
Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure (AJMC)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales